



Real-World Adoption, Treatment Patterns, and Utilization of Tumor Treating Fields in Non-Small Cell Lung Cancer

M. Munir¹, C.J. Wang², S. Khagi³, S. Sarkisian⁴, M. Tate⁵, **S. Chun⁶**, B.K. Chang⁷, H. Albandar⁷, K. Ku⁸, W. Iams⁹, R. Kulkarni¹⁰, E. Luk¹¹, E. Patel¹², M.D. Craig¹³, R. Kotecha¹
¹Herbert Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL, USA; ²Willis-Knighton Health Radiation Oncology Clinic, Shreveport, LA, USA; ³Hoag Family Cancer Institute, Newport Beach, CA, USA; ⁴Frederick Health-James M. Stockman Cancer Institute, Frederick, MD, USA; ⁵**MD Anderson Cancer Center, Houston, TX, USA**; ⁶Radiation Oncology Associates, Fort Wayne, IN, USA; ⁷St. Luke's Cancer Care Associates, Allentown, PA, USA; ⁸The US Oncology Network-Illinois Cancer Care, Bloomington, IL, USA; ⁹Tennessee Oncology, Nashville, TN, USA; ¹⁰Dayton Physicians Network, Dayton, OH, USA; ¹¹Messino Cancer Centers, Sylva, NC, USA; ¹²RWJBarnabas Health, Somerset, NJ, USA; ¹³Mon Health Cancer Center/Vandalia Health, Morgantown, WV, USA.
Presenting Author: Stephen Chun, MD • sgchun@mdanderson.org ; Correspondence: Rupesh Kotecha, MD • rupeshk@baptisthealth.net



INTRODUCTION

- Tumor Treating Fields (TTFields) disrupt cancer-cell mitosis & enhance antitumor immunity
- Stage IV NSCLC indication - TTFields with docetaxel/PD-(L)1 therapy were FDA approved after 1st-line platinum chemotherapy (phase 3 LUNAR study)
- Purpose: characterize real-world prescription/utilization of TTFields for Stage IV NSCLC post-FDA approval

METHODS

- Institutional review board approval was obtained.
- Retrospective analysis of subjects with prescribed TTFields for Stage IV NSCLC
- Data source: prescriber records from device manufacturer database.
- Inclusion criteria: patients utilizing TTFields for ≥30 days.
- Variables of interest: monthly prescription trends, provider specialty, practice setting, line of therapy, concurrent systemic therapy, prior checkpoint immunotherapy, and daily TTF use

DISCUSSION AND CONCLUSION

- TTFields was adopted across community, hospital-based, and academic practice settings.
- Multidisciplinary utilization led primarily by medical oncology and radiation oncology.
- TTFields most commonly prescribed with checkpoint immunotherapy and docetaxel.
- Median daily device use was 10.4 hours daily.
- Early real-world data show broad uptake of TTFields for Stage IV NSCLC indication.
- Future studies will correlate usage, systemic therapy sequencing and toxicity to clinical outcomes.

REFERENCES

1. Leal T, et al. Tumor Treating Fields with standard systemic therapy in metastatic NSCLC after platinum: LUNAR phase III study.
2. U.S. Food and Drug Administration. TTFields approval for metastatic NSCLC after progression on or after platinum-based therapy, 2024

RESULTS

